GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/HCC/Key Differences in Y90 vs. SBRT Dosing in HCC

Key Differences in Y90 vs. SBRT Dosing in HCC

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated November 1, 2025

Quick Answer

**Role of Radiotherapy in HCC (Hepatocellular Carcinoma):** Radiotherapy plays a critical role in treating HCC, particularly for patients who are not candidates for surgery or liver transplantation. It aims to deliver targeted radiation to destroy tumor cells while sparing healthy liver tissue.


**Role of Radiotherapy in HCC (Hepatocellular Carcinoma):**

Radiotherapy plays a critical role in treating HCC, particularly for patients who are not candidates for surgery or liver transplantation. It aims to deliver targeted radiation to destroy tumor cells while sparing healthy liver tissue. Advanced techniques, such as SBRT and Y90 radioembolization, are commonly used for localized disease and provide non-invasive tumor control with minimal systemic side effects.

**What is Y90?**

Y90 (Yttrium-90) radioembolization is a locoregional therapy that involves injecting radioactive microspheres directly into the hepatic artery, targeting liver tumors. These microspheres lodge in the tumor's arterioles and emit beta radiation, delivering a highly localized dose over several days. The radiation penetrates only 2–3 mm into tissue, resulting in a heterogeneous dose distribution within the tumor.

**What is SBRT?**

SBRT (Stereotactic Body Radiation Therapy) is a highly precise form of external beam radiation therapy that delivers intense doses of radiation to the tumor in a few sessions, typically over a few minutes per session. SBRT is known for delivering a uniform dose of radiation, with high tumor control rates due to its precision and ability to spare surrounding healthy tissue.

**Key Differences in Y90 vs. SBRT Dosing in HCC:**

1. **Dose Uniformity:** SBRT delivers a uniform dose across the tumor, while Y90 provides a highly heterogeneous dose due to microsphere deposition in arterioles with limited penetration (2–3 mm).

2. **Dose Distribution:** Y90 doses vary significantly within the tumor mass, whereas SBRT provides consistent dosing throughout the target region.

3. **Dose Rate:** SBRT administers radiation over minutes per session, while Y90 delivers radiation gradually over several days due to Y90's half-life (~64 hours).

4. **Biological Effect:** Y90's slower radiation delivery allows cellular repair of sublethal DNA damage during treatment, reducing its biological effectiveness per Gy compared to SBRT.

5. **Dose Equivalence:** A Y90 dose of ~400 Gy corresponds to an SBRT dose of 40–50 Gy in terms of tumoricidal effect due to the temporal protraction effect.

**Summary of the Text:**

Radiotherapy is crucial for treating HCC, especially for patients ineligible for surgery. Y90 is a locoregional therapy using radioactive microspheres to deliver heterogeneous radiation over days, while SBRT is a precise external beam therapy delivering uniform radiation in minutes. Key differences include dose uniformity, distribution, rate, biological effects, and equivalence, with Y90's 400 Gy being biologically similar to SBRT's 40–50 Gy.

Related Q&A

Liver Stiffness for HCC Risk in MASLD: Hepatology | July 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is now the fastest-growing cause of hepatocellular carcinoma (HCC). Because a substantial proportion of MASLD-related HCC develops before cirrhosis, better tools are needed to identify high-risk patients who...

Durvalumab Plus Tremelimumab in Real-World HCC: JGH | May 2026

Introduction: The HIMALAYA trial established durvalumab plus tremelimumab (STRIDE) as a first-line treatment for unresectable hepatocellular carcinoma (HCC). However, many real-world patients do not meet the strict eligibility criteria of clinical trials. This multicenter study...

ALBI Grade and Sarcopenia in Unresectable HCC: IJG | July 2026

Introduction: Prognosis in unresectable hepatocellular carcinoma (HCC) depends not only on tumor burden but also on liver function and nutritional status. This study evaluated the prognostic value of ALBI grade, EZ-ALBI grade, and sarcopenia in...

HCC Surveillance Saves Lives: Frontline Gastroenterology | July 2026

Introduction: Hepatocellular carcinoma (HCC) surveillance enables earlier diagnosis and improves survival. This largest UK multicenter study evaluated how patients are diagnosed in routine clinical practice and identified major gaps in the surveillance pathway. Why was...

Yttrium-90 Radioembolization for HCC: The Lancet Regional Health | July 2026

Introduction: Selective internal radiation therapy (SIRT) using yttrium-90 (Y90) glass microspheres is an established locoregional treatment for hepatocellular carcinoma (HCC), but guideline recommendations remain inconsistent. This large prospective multicenter study evaluated the real-world effectiveness, safety,...

Bleeding Risk with Immunotherapy in Advanced HCC: JHEP Reports | July 2026

Introduction: Atezolizumab–bevacizumab (A/B) and durvalumab–tremelimumab (STRIDE) are preferred first-line treatments for advanced hepatocellular carcinoma (HCC). Because bevacizumab inhibits VEGF, concerns remain regarding bleeding and thromboembolic complications in patients with underlying cirrhosis and portal hypertension. Why...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer